BONE BIOLOGICS CORP
BBLGNASDAQTrading Snapshot
- Day Range
- $0.91 – $0.92
- 52-Week Range
- $0.83 – $4.13
- Volume
- $2.65B
- Avg Volume
- $2.93B
- Shares Outstanding
- 1.8M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $195,866
- Last Q Revenue
- $53,968
- P/E Ratio
- -0.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.59
- Dividend Yield
- 0.00%
Why Investors Own BBLG
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BONE BIOLOGICS CORP
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
BONE BIOLOGICS CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BBLG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BONE BIOLOGICS CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.